GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » InnoCan Pharma Corp (FRA:IP4) » Definitions » Inventories, Finished Goods

InnoCan Pharma (FRA:IP4) Inventories, Finished Goods : €0.00 Mil (As of Sep. 2024)


View and export this data going back to 2020. Start your Free Trial

What is InnoCan Pharma Inventories, Finished Goods?

InnoCan Pharma's annual finished goods increased from Dec. 2021 (€0.29 Mil) to Dec. 2022 (€0.86 Mil) and increased from Dec. 2022 (€0.86 Mil) to Dec. 2023 (€1.41 Mil).


InnoCan Pharma Inventories, Finished Goods Historical Data

The historical data trend for InnoCan Pharma's Inventories, Finished Goods can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InnoCan Pharma Inventories, Finished Goods Chart

InnoCan Pharma Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Inventories, Finished Goods
Get a 7-Day Free Trial - 0.19 0.29 0.86 1.41

InnoCan Pharma Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Inventories, Finished Goods Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 1.41 - - -

InnoCan Pharma Inventories, Finished Goods Calculation

The products in a manufacturer's inventory that are completed and are waiting to be sold.


InnoCan Pharma Business Description

Traded in Other Exchanges
Address
1015, 926 - 5 Avenue SW, Calgary, AB, CAN, T2P 0N7
InnoCan Pharma Corp is a pharmaceutical tech company that focuses on the development of several drug delivery platforms combining cannabidiol with other pharmaceutical ingredients as well as the development and sale of CBD-integrated pharmaceuticals. Geographically, it derives a majority of its revenue from the United States.

InnoCan Pharma Headlines

No Headlines